In-Licensing Opportunity
A large client based in the USA wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.
Staying abreast of the rapid changes in the healthcare environment is paramount. Through a combination of robust data, and expert opinion and analysis, we provide real-time actionable insights to our partners and enable them to make informed decisions.
Some of our key services include:
Our competitive intelligence consulting services provide research-based solutions to help you gain a competitive advantage. Our strategy considers the perspectives of customers, suppliers, business competitors, and others. We gather market data from all corners of the industry and transform it into useful information. Our Competitive Intelligence team, composed of analysts, senior analysts, managers, and key opinion leaders (KOLs), provides our partners with the most up-to-date and accurate intelligence available.
One of the major challenges drug developers grapple with in the rare diseases area is the dearth in reliable and accurate epidemiology studies. We bridge this gap by conducting in-depth interviews with the key opinion leaders along with exhaustive literature searches in the 7MM [the US, EU4 (Germany, Italy, Spain, France) and the UK, and Japan] geographies. Our patient-based model approach garners insights around the patient journey, helping our partners understand the treatable patient pool for a given rare indication. The in-depth epidemiological assessment will help you to track all the updates regarding the key challenges and unmet needs in the emerging market and how companies are working to tackle the rising prevalence.
Epidemiology Insights provides a framework for epidemiological research and understanding of various indications, such as prevalence/incidence and geographic distribution, clinical manifestations, etiology, pathophysiology, severity, and diagnosis. Our in-depth indication epidemiology analysis will assist you in tracking the growth opportunities for rare diseases across various geographies.
The drug development process is a long and expensive affair and thus, it is imperative for an innovator to understand the market one is getting into.
Key strengths of our models include:
Our keen market forecast insights keep clients up to date on recent developments in the healthcare industry and provide an edge in the competitive pharmaceutical market, which further assists them in understanding the granular view of the market and understanding how the market will evolve over the next decade.
For any orphan indication, putting the right price on a drug is extremely challenging given the lack of quality-adjusted life year (QALY) and health technology assessments (HTA), and limited analogs. By understanding the key elements that define the payer’s purchasing decision and the growing focus on value-based pricing, we help our partners develop the optimal pricing strategy that can significantly improve their product's profitability and market share.
We are a truly multidisciplinary team with years of market access, pricing, and reimbursement experience. This enables us to weigh in data and market research advice from payers/KOLs, as well as an understanding of the future environment, and provide future-proof advice.
Unsure which indication to focus on? Is there a bigger market potential in indication A compared to indication B? These are some of the questions innovators grapple with. Given the long duration of drug development, huge capital requirement, and high failure rate, it becomes essential for the players to understand the granularity of this therapy area and how to play in the market.
DelveInsight offers a solution by walking clients through the current and evolving standards of care to comprehensively estimate the correct value and physician/payer’s perspective, helping them in defining the correct target patient populations and investing wisely in lucrative indications.
DelveInsight analysts collaborate with the client team to develop intelligent criteria, create assessment scenarios based on reliable parameters of importance, and define situations as a result of potential successes and failures. Our Indication Prioritization service helps companies create a solid strategy for R&D by understanding future market dynamics through market modeling, unmet medical needs for future understanding of treatment regimens, and so on.
Whether in development or commercial activities, companies frequently seek partnerships that can lead to a win-win situation for the parties involved. The prioritizing interests create the inherent challenge of finding another company with similar interests. DelveInsight, with its proprietary partnering methodology and robust network, helps clients navigate through complex torrents of industry collaborations and assists in identifying the right partner(s) for drug development or commercialization. Through an assessment of unmet needs and strategic alignment, and validation of business perspectives, we help scout the right candidates for a potential collaboration. Our partner assessment services also help the client in identifying, monitoring, and evaluating organizational barriers for maintaining a strong market foothold.
Key takeaways from our service include:
Along with the syndicated services, we also offer solutions tailor-made to the specific needs of our partners. Our customized offerings are designed to meet your specific research needs. Customer-centric, solution-oriented approach to assisting our client partners in gaining an advantage and amplifying their growth prospects. We believe in adding value to our customers' businesses by accelerating their growth through strategic advisory services that assist in making sound business decisions. Our customized services help in creating opportunistic paths that are strategically aligned with our client's vision.
Some of the key services custom-made for our partners include:
Featured Newsletter
Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yielded a great success in recent years. Promising antitumor effects have been demonstrated in several different solid and hematological malignancies by the introduction of PD-1/PDL-1 blockade therapy. There is a growing concern about whether they are comparable as the use of PD-1/PDL-1 inhibitors is increasing in number for the clinical treatment of cancer.
A large client based in the USA wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.
A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs.
A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies.
To succeed in the rare disease market, research companies must have a distinct business model and a carefully tailored set of capabilities in R&D, market access, and commercial aspects. We provide the best strategy and operating model required to succeed in this winner-take-all market.